Peptide Calculator

BPC-157 & TB-500 Blend Dosage Calculator

Calculate BPC-157 + TB-500 blend reconstitution, component ratio math, and U-100 syringe units.

BPC-157 & TB-500 Blend Pre-filled Reconstitution Tool

Pre-loaded with common BPC-157 & TB-500 Blend vial size and reconstitution ratios.

U-100 Syringe Standard
Total compound mass
mg
Added diluent
mL
mcg
Standard U-100
Calculation OutputU-100 Calibrated
Draw Exactly To:
10.0Units
Line 10 on your syringe (0.10 mL volume)
Concentration
2.50 mg/mL
Doses per Vial
20 Doses
Visual Syringe Indicator1.0 mL Syringe

Reconstitution Summary Card

Stored locally on your device (No account needed)

Author:Rohit Nimbalkar
Last updated:
Sources checked: 2026-11-10
Editorial PolicyReport Error

📌At a Glance: BPC-157 & TB-500 Blend Reconstitution Arithmetic

  • Blend Components: Co-lyophilized combination of pentadecapeptide BPC-157 and actin-sequestering analogue TB-500.
  • The Shared-Volume Law: Adding liquid diluent dilutes both compounds equally across the total volume; you cannot alter the ratio between components after reconstitution.
  • Measurement Resolution: On a standard U-100 syringe (100 units = 1.0 mL), each unit delivers 0.01 mL of solution containing exact fixed fractions of both peptides.
  • Multi-Component Vials: Multi-peptide formulations with three or more active compounds (such as the Klow blend calculator) follow the identical component concentration arithmetic.
⚖️Regulatory & Compound Status
Verified: 2026-11-10

Neither BPC-157 nor TB-500 (Thymosin Beta-4 fragment) is an FDA-approved human drug. In late 2023, the FDA placed BPC-157 on the Category 2 Bulk Drug Substances list under 503A compounding due to potential immunogenicity and lack of safety data. Both compounds are prohibited at all times (in-competition and out-of-competition) by WADA under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics).

Official Sources:Safety Risks Associated with Certain Bulk Drug Substances Nominated for 503A/503B Compounding,World Anti-Doping Code International Standard: Prohibited List (S2: Peptide Hormones),Analytical Procedures and Acceptance Criteria for Synthetic Peptide Drug Substances
ℹ️What This Tool Cannot Tell You
  • A therapeutic protocol, injury recovery cycle, or human administration guideline.
  • Whether co-lyophilized mixtures are suitable for human clinical use (neither agent has received FDA human drug approval).
  • How to independently administer one compound without delivering the exact proportional amount of the other from a pre-mixed vial.
  • Legality or compliance within sanctioned athletic competitions (both substances are prohibited by WADA).

This tool converts volumetric liquid measurements and syringe tick marks only. It does not provide medical guidance, dosing schedules, or clinical administration protocols. Review our Medical & Research Disclaimer.

What Is the BPC-157 & TB-500 Blend?

The BPC-157 & TB-500 Blend is a pre-mixed, co-lyophilized multi-peptide formulation combining equal mass ratios of BPC-157 and TB-500 into a single research vial. In scientific discussions and enthusiast communities, this combination is often referred to as the wolverine stack or wolverine blend in reference to preclinical cellular tissue repair models.

Co-lyophilizing BPC-157 and TB-500 simplifies laboratory protocols by eliminating the need to reconstitute and draw two separate vials. Reconstituting this blend with our peptide calculator and sterile bacteriostatic water ensures fixed proportional delivery of both compounds with every syringe draw.

BPC-157 & TB-500 Blend Dosage Chart

In a 10 mg total blend vial containing 5 mg BPC-157 and 5 mg TB-500 (1:1 ratio), adding 2.0 mL of bacteriostatic water creates a concentration of 2,500 mcg/mL per compound. A 10 unit draw on a U-100 syringe delivers 250 mcg of BPC-157 and 250 mcg of TB-500 simultaneously.

Vial SizeBac Water AddedConcentrationExample AmountDraw Units (U-100)
10 mg Total (5/5)2.0 mL2.5 mg/mL each250 mcg BPC / 250 mcg TB10.0 Units
10 mg Total (5/5)2.0 mL2.5 mg/mL each500 mcg BPC / 500 mcg TB20.0 Units
20 mg Total (10/10)4.0 mL2.5 mg/mL each250 mcg BPC / 250 mcg TB10.0 Units
15 mg Total (10/5)3.0 mL3.33/1.67 mg/mL500 mcg BPC / 250 mcg TB15.0 Units

BPC-157 & TB-500 Blend Reconstitution Reference Matrix

The deterministic matrix below displays component concentrations and microgram resolution per U-100 syringe mark across standard blend vial configurations (5 + 5 mg and 10 + 10 mg) with 1.0 mL, 2.0 mL, and 3.0 mL of bacteriostatic water. For single-agent calculations or other tissue research peptides, see BPC-157 calculator, TB-500 calculator, GHK-Cu calculator, and for three or more co-lyophilized components, vials with three or more components work the same way. For individual diluent volume standards, see the BPC-157 bacteriostatic water guide.

Vial CompositionBac Water AddedEach Component Conc.Total Peptide Conc.Per U-100 Mark (0.01 mL)Draw for 250/250 mcg Target
5 mg + 5 mg (10 mg total)1.0 mL5.0 mg/mL (5,000 mcg/mL)10.0 mg/mL50 mcg each component5.0 units (0.05 mL)
5 mg + 5 mg (10 mg total)2.0 mL2.5 mg/mL (2,500 mcg/mL)5.0 mg/mL25 mcg each component10.0 units (0.10 mL)
5 mg + 5 mg (10 mg total)3.0 mL1.67 mg/mL (1,667 mcg/mL)3.33 mg/mL16.7 mcg each component15.0 units (0.15 mL)
10 mg + 10 mg (20 mg total)1.0 mL10.0 mg/mL (10,000 mcg/mL)20.0 mg/mL100 mcg each component2.5 units (0.025 mL)
10 mg + 10 mg (20 mg total)2.0 mL5.0 mg/mL (5,000 mcg/mL)10.0 mg/mL50 mcg each component5.0 units (0.05 mL)
10 mg + 10 mg (20 mg total)3.0 mL3.33 mg/mL (3,333 mcg/mL)6.67 mg/mL33.3 mcg each component7.5 units (0.075 mL)

Worked Dual-Component Arithmetic: 5 mg + 5 mg Vial with 2.0 mL Diluent

Example Parameters:
  • Co-lyophilized vial: 5 mg BPC-157 + 5 mg TB-500 (10 mg combined active peptide mass)
  • Diluent volume: 2.0 mL bacteriostatic water
  • Target research quantity: 250 mcg (0.25 mg) of each peptide
  • Syringe standard: U-100 insulin syringe (100 units = 1.0 mL = 0.01 mL per unit)
Step-by-Step Calculation:
  1. Calculate individual component concentration: 5 mg BPC-157 ÷ 2.0 mL = 2.5 mg/mL (2,500 mcg/mL) and 5 mg TB-500 ÷ 2.0 mL = 2.5 mg/mL (2,500 mcg/mL).
  2. Calculate microgram delivery per syringe unit mark: 2,500 mcg/mL ÷ 100 units/mL = 25 mcg per U-100 unit mark for each compound.
  3. Calculate draw volume required for 250 mcg: 250 mcg ÷ 2,500 mcg/mL = 0.10 mL.
  4. Convert volume to syringe markings: 0.10 mL × 100 units/mL = 10 units on a U-100 syringe barrel.
  5. Deterministic reverse back-check: 10 units × 25 mcg/unit = 250 mcg BPC-157 and 10 units × 25 mcg/unit = 250 mcg TB-500 (0.10 mL × 2.5 mg/mL = 0.25 mg each), confirming exact mathematical agreement.
Result:

Draw exactly 10 units (0.10 mL) on a standard U-100 insulin syringe to deliver 250 mcg BPC-157 and 250 mcg TB-500 simultaneously.

Note: Arithmetic verification: 10 units delivers 0.25 mg of each compound. On a 0.3 mL (30-unit) syringe barrel, a 10-unit draw offers high volumetric readability.

How to Reconstitute the BPC-157 & TB-500 Blend

Reconstituting a multi-peptide blend vial follows standard laboratory diluent procedures, ensuring complete solubility of both active lyophilized compounds.

Syringe Reading Diagram

U-100 Syringe Graduation & Measurement Line (BPC-157 & TB-500 Blend)

010 U20304050 U (0.5 mL)60708090100 U (1.0 mL)Align Leading Black Ring to 10 Units

5 Standard Reconstitution Steps for BPC-157 & TB-500 Blend

  1. Sanitize the stoppers of both the blend vial and bacteriostatic water vial with 70% isopropyl alcohol prep pads.
  2. Draw 2.0 mL of bacteriostatic water using a sterile mixing syringe.
  3. Inject water slowly down the interior glass wall of the blend vial.
  4. Swirl the vial gently until both compounds fully dissolve into a transparent solution.
  5. Store reconstituted blend in a laboratory refrigerator at 2°C–8°C.

❄️ Storage & Shelf-Life Notice (BPC-157 & TB-500 Blend)

Store reconstituted multi-dose vials refrigerated at 2°C–8°C (36°F–46°F) and never freeze. Under FDA multi-dose sterile vial guidance, discard opened multi-dose vials within 28 days of first puncture.

⚠️ Common Preparation Mistakes to Avoid

Calculating draw units based on combined total mass (10 mg) rather than individual component concentration, shaking the vial violently, and freezing reconstituted liquid.

BPC-157 & TB-500 Blend Dosing FAQ

Why is the BPC-157 & TB-500 blend sometimes called the Wolverine stack?↓
"Wolverine stack" is an informal nickname used in online discussions for co-lyophilized BPC-157 and TB-500 vials. Neither compound is FDA-approved for human use, and this calculator provides only volumetric concentration math from the masses printed on a label.
How much bac water do I add to a 10mg BPC-157/TB-500 blend vial?↓
Adding 2.0 mL of bac water to a 10 mg blend vial (5mg BPC / 5mg TB) gives 2,500 mcg/mL of each peptide. A 10 unit draw provides 250 mcg of BPC-157 and 250 mcg of TB-500.
Does a calculator verify stability when BPC-157 and TB-500 share one vial?↓
No. Published chemical compatibility and stability data for co-lyophilized unapproved mixtures are limited. Store refrigerated (2°C–8°C) and follow FDA multi-dose sterile vial discard guidance (28 days after first puncture).
Can I freeze the reconstituted blend?↓
No. Liquid peptide solutions must never be frozen. Store upright in a refrigerator between 2°C and 8°C.
How do draw units work for multi-peptide vials?↓
Reconstitution volume applies to all compounds in the vial simultaneously. Draw units are calculated based on your primary target compound, delivering proportional doses of the co-lyophilized partner.

Related Peptide Calculators & Stacks

BPC-157
Calculate reconstitution volume, solution concentration, and U-100 syringe units for research BPC-157 vials.
Calculate BPC-157→
GHK-Cu
Calculate reconstitution volume, solution concentration, and U-100 syringe units for high-mass GHK-Cu vials.
Calculate GHK-Cu→
Klow Blend
Calculate multi-component peptide blend reconstitution, concentration ratios, and U-100 syringe units from your vial label.
Calculate Klow Blend→
TB-500
Calculate reconstitution volume, solution concentration, and U-100 syringe units for research TB-500 vials.
Calculate TB-500→

Related Reconstitution & Dosing Guides

View All FAQs→
BPC-157 FAQ
How Much Bac Water for BPC-157?
→
GHK-Cu FAQ
How Much Bac Water for GHK-Cu?
→
General Peptide FAQ
How to Reconstitute Peptides?
→

Scientific & Regulatory References

View Full Sources Registry→

The mathematical formulas on this page are deterministic volumetric conversions. Non-mathematical parameters, regulatory status notes, and chemical safety guidelines are referenced directly to the primary sources cataloged below:

  1. [1]
    Safety Risks Associated with Certain Bulk Drug Substances Nominated for 503A/503B Compounding
    U.S. Food and Drug Administration•Type: fda communication•Verified: 2026-10-20

    FDA Category 2 classification covering safety considerations for BPC-157, AOD-9604, and CJC-1295.

  2. [2]
    World Anti-Doping Code International Standard: Prohibited List (S2: Peptide Hormones)
    World Anti-Doping Agency (WADA)•Type: regulatory list•Verified: 2026-10-20

    Prohibits growth hormone secretagogues (GHS), GH fragments, BPC-157, TB-500, and metabolic modulators.

  3. [3]
    Stable Gastric Pentadecapeptide BPC 157 in Clinical Pharmacology and Gastric Protection
    Current Pharmaceutical Design (PubMed PMID: 20388954)•Type: peer reviewed•Verified: 2026-10-20

    Evaluation of 15-amino acid sequence stability in gastric acid and neutral buffered aqueous solution.

  4. [4]
    Thymosin Beta-4: Actin-Sequestering Protein and Its Structural Derivatives
    Annals of the New York Academy of Sciences (PubMed PMID: 17872477)•Type: peer reviewed•Verified: 2026-10-20

    Biochemical characterization of 43-amino acid Tβ4, actin binding via LKKTET motif, and peptide fragments.

  5. [5]
    Bacteriostatic Water for Injection, USP Multi-Dose Prescribing Details
    U.S. National Library of Medicine (DailyMed / Hospira / Pfizer)•Type: fda label•Verified: 2026-10-20

    Sterile multi-dose diluent specification containing 0.9% (9 mg/mL) benzyl alcohol preservative.

  6. [6]
    FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
    U.S. Food and Drug Administration (FDA CDER)•Type: fda communication•Verified: 2026-11-08

    FDA safety alert detailing risks of unapproved compounded GLP-1 drugs, dosing errors, lack of pre-market review, improper cold-chain shipping temperatures, and recommendation to discard multi-dose sterile vials 28 days after first puncture.

  7. [7]
    USP General Chapter <797>: Pharmaceutical Compounding — Sterile Preparations
    United States Pharmacopeial Convention (USP)•Type: standard•Verified: 2026-10-20

    Standards for beyond-use dates (BUD), refrigeration controls (2°C–8°C), and multi-dose sterility.

  8. [8]
    Embecta Ultra-Fine™ U-100 Insulin Syringe Product Specifications
    embecta (formerly BD Diabetes Care)•Type: manufacturer spec•Verified: 2026-11-08

    Manufacturer specifications for sterile single-use U-100 insulin syringes (0.3 mL, 0.5 mL, and 1.0 mL capacities with 1-unit and 1/2-unit scales).